Supernus Pharmaceuticals Return on Tangible Equity 2011-2024 | SUPN

Current and historical return on tangible equity values for Supernus Pharmaceuticals (SUPN) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Supernus Pharmaceuticals Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2024-09-30 $0.06B $0.35B 22.10%
2024-06-30 $0.01B $0.28B 2.29%
2024-03-31 $-0.02B $0.23B -8.74%
2023-12-31 $0.00B $0.21B 0.65%
2023-09-30 $0.03B $0.15B 21.05%
2023-06-30 $0.04B $0.14B 51.50%
2023-03-31 $0.05B $0.11B 118.18%
2022-12-31 $0.06B $0.07B 2033.33%
2022-09-30 $0.04B $0.01B -107.80%
2022-06-30 $0.06B $-0.02B 100.00%
2022-03-31 $0.07B $-0.05B 49.01%
2021-12-31 $0.05B $-0.09B 22.20%
2021-09-30 $0.08B $0.39B 24.38%
2021-06-30 $0.10B $0.36B 33.86%
2021-03-31 $0.11B $0.32B 44.44%
2020-12-31 $0.13B $0.30B 40.00%
2020-09-30 $0.13B $0.22B 33.59%
2020-06-30 $0.12B $0.17B 25.56%
2020-03-31 $0.12B $0.59B 21.41%
2019-12-31 $0.11B $0.57B 22.09%
2019-09-30 $0.11B $0.53B 22.35%
2019-06-30 $0.11B $0.49B 23.93%
2019-03-31 $0.10B $0.45B 25.46%
2018-12-31 $0.11B $0.42B 29.90%
2018-09-30 $0.10B $0.39B 30.60%
2018-06-30 $0.09B $0.36B 31.07%
2018-03-31 $0.07B $0.32B 30.32%
2017-12-31 $0.06B $0.23B 27.70%
2017-09-30 $0.06B $0.22B 30.52%
2017-06-30 $0.10B $0.20B 59.71%
2017-03-31 $0.10B $0.18B 65.75%
2016-12-31 $0.09B $0.16B 74.59%
2016-09-30 $0.08B $0.16B 80.00%
2016-06-30 $0.03B $0.09B 32.10%
2016-03-31 $0.02B $0.08B 23.84%
2015-12-31 $0.01B $0.09B 19.65%
2015-09-30 $0.01B $0.06B 18.49%
2015-06-30 $0.01B $0.07B 9.62%
2015-03-31 $0.01B $0.06B 14.46%
2014-12-31 $-0.01B $0.04B -34.11%
2014-09-30 $-0.04B $0.03B -122.31%
2014-06-30 $-0.06B $0.03B -233.66%
2014-03-31 $-0.09B $0.03B -335.85%
2013-12-31 $-0.09B $0.03B -303.33%
2013-09-30 $-0.08B $0.01B -228.97%
2013-06-30 $-0.07B $0.04B -183.44%
2013-03-31 $-0.06B $0.04B -138.36%
2012-12-31 $-0.05B $0.06B -160.68%
2012-09-30 $0.05B $0.02B 284.06%
2012-06-30 $0.05B $0.04B 453.33%
2012-03-31 $0.05B $-0.00B 2650.00%
2011-12-31 $0.05B $0.01B 2266.67%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.962B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00